Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.59 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.54 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.54 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TET3 | O43151 | 1/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.47 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.47 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.47 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274435 | 1.00 | EGLN1 (0.59) | EGLN1BBOX1FTOEGLN3THRA | |
| SCHEMBL4073242 | 0.82 | EGLN1 (0.70) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL522834 | 0.80 | EGLN1 (0.58) | EGLN1BBOX1FTOEGLN3HIF1AN | |
| SCHEMBL522393 | 0.79 | EGLN1 (0.66) | EGLN1BBOX1FTO | |
| SCHEMBL522827 | 0.79 | EGLN1 (0.57) | EGLN1BBOX1FTOEGLN3THRA | |
| SCHEMBL1216041 | 0.79 | EGLN1 (0.66) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL523800 | 0.79 | EGLN1 (0.66) | EGLN1 | |
| SCHEMBL31028961 | 0.79 | EGLN1 (0.66) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL31501044 | 0.78 | EGLN1 (0.68) | EGLN1BBOX1FTOEGLN3 | |
| SCHEMBL821293 | 0.78 | EGLN1 (0.68) | EGLN1BBOX1FTOEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101242817-B | HIF1 alpha modulators purposes in treatment cancer | 菲布罗根公司 | 2016-08-31 | — | — | CN | claimed |
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | claimed |
| EP-1919463-B1 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2010-06-09 | — | — | EP | claimed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| EP-4142721-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | Bioage Labs, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20210353612-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | BioAge Labs, Inc. | 2021-11-18 | — | — | US | disclosed |
| WO-2021222424-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | BioAge Labs, Inc. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-9775902-B2 | Compounds and methods for treatment of stroke | FIBROGEN, INC (US) | 2017-10-03 | — | — | US | disclosed |
| US-8530404-B2 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110263644-A1 | Compounds and Methods for Treatment of Stroke | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-1919463-B9 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN INC (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-1991269-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF STROKE | FIBROGEN, INC. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070259960-A1 | Compounds and methods for treatment of stroke | FIBROGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007097929-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF STROKE | FIBROGEN, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353612-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | HIF1AN, HIF1A, P4HA1 | EGLN1 11/4885BBOX1 298/4885FTO 730/4885 |
| US-20110263644-A1 | Compounds and Methods for Treatment of Stroke | PLAT, SERPINE1, PLG | EGLN1 740/4885BBOX1 982/4885FTO 3629/4885 |
| US-20070259960-A1 | Compounds and methods for treatment of stroke | PLAT, SERPINE1, PLG | EGLN1 740/4885BBOX1 982/4885FTO 3629/4885 |
| US-20110015223-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | EGLN1 21/4885BBOX1 1307/4885FTO 2512/4885 |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | TP53, MKI67, HDGF | EGLN1 98/4885BBOX1 967/4885FTO 4455/4885 |
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | EPOR, MCL1, HIF1AN | EGLN1 25/4885BBOX1 713/4885FTO 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.